Emerging Biotech Company Ikonisys Inc. Announces Appointment Of Bracco Diagnostics CEO Carlo Medici To Its Board Of Directors NEW HAVEN, Conn., April 18/PRNewswire/ -- Ikonisys, Inc., announced today that Carlo Medici, Chief Executive Officer of Bracco Diagnostics, Inc., joined its board of directors following a partnering agreement between Ikonisys and The Bracco Group, a world leader in diagnostic imaging. Bracco Diagnostics is the U.S. subsidiary of Italy-based The Bracco Group. "Bracco Diagnostics President and CEO Carlo Medici brings to Ikonisys nearly 20 years of experience in the health care industry," said Dr. Petros Tsipouras, Chief Executive Officer of Ikonisys, the New Haven, Conn.-based biotechnology company at the forefront of cell-based diagnostics. Medici is the former president of Roche Diagnostic Systems, a division of Hoffmann-LaRoche Inc., and recently served as corporate vice president and general manager for Covance Clinical Services, where he was responsible for their clinical trials unit in the Americas. "Mr. Medici's vast experience in the medical diagnostic field will be a tremendous asset to our company as we develop new technology in the area of cell-based diagnostics," Dr. Tsipouras said. "His involvement and our relationship with Bracco further validate our unique process." Medici's appointment comes after Ikonisys and The Bracco Group, the parent company of Bracco Diagnostics, formed a partnership. Italy-based Bracco is an equity investor in Ikonisys and will assist the company in its clinical trials of a Down Syndrome diagnostic test set to begin this summer. Bracco plans to market the test in its home market. The Down Syndrome test is the first product for Ikonisys, which uses a systems-integrated approach to cell-based diagnostics, converging molecular and cellular biology, microscopy, image analysis and information technology. Ikonisys Inc., a privately held company, is harnessing cell-based diagnostics through the development of a highly flexible proprietary platform for both the identification of cells of interest and diagnostic signals generated within those cells. It provides the capability to analyze large volumes of information in an accurate and rapid manner. The applications of this technology will allow early detection of genetic abnormalities and cancer detection and monitoring at a lower cost and less invasively than current diagnostic methods. Contact: Angel Streeter of The TransMedia Group, 561-750-9800, ext. 21. AStreeter@transmediagroup.com